SCHEMBL23728529

SCHEMBL23728529

O=C(O)c1c(Cl)nn2cccnc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 2/20 0.45
APOBEC3G Q9HC16 1/20 0.45
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KCNQ3 O43525 2/20 0.38
KCNQ2 O43526 2/20 0.38
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.38
PIK3CG P48736 1/20 0.37
HTR6 P50406 1/20 0.37
RORC P51449 1/20 0.36
PDE2A O00408 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18049709 0.87 HPGD (0.45) APOBEC3AAPOBEC3GALDH1A1L3MBTL1HPGD
SCHEMBL462895 0.85 HPGD (0.41) APOBEC3AAPOBEC3GALDH1A1L3MBTL1HPGD
SCHEMBL16619547 0.80 PIK3CG (0.45) APOBEC3AAPOBEC3GPIK3CG
SCHEMBL3714513 0.80 PIK3CG (0.51) APOBEC3AAPOBEC3GALDH1A1L3MBTL1HPGD
SCHEMBL18208430 0.79 PIK3CG (0.44) APOBEC3AAPOBEC3GPIK3CG
SCHEMBL23728612 0.78 HPGD (0.44) APOBEC3AALDH1A1HPGDSMN1; SMN2NPC1
SCHEMBL26172231 0.78 HTR6 (0.53) APOBEC3AAPOBEC3GALDH1A1L3MBTL1HPGD
SCHEMBL29703829 0.77 KMT2A (0.44) APOBEC3AAPOBEC3GALDH1A1L3MBTL1KMT2A
SCHEMBL23013921 0.77 KMT2A (0.44) APOBEC3AAPOBEC3GALDH1A1L3MBTL1KMT2A
SCHEMBL23728636 0.76 PDE2A (0.44) APOBEC3AAPOBEC3GALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 APOBEC3A 219/4885APOBEC3G 151/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.